Unum Therapeutics Inc (UMRX) Given $19.67 Average Target Price by Brokerages

Unum Therapeutics Inc (NASDAQ:UMRX) has received a consensus broker rating score of 1.63 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company.

Brokers have set a twelve-month consensus target price of $19.67 for the company and are predicting that the company will post ($0.33) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Unum Therapeutics an industry rank of 157 out of 265 based on the ratings given to related companies.

UMRX has been the topic of several research analyst reports. Morgan Stanley initiated coverage on shares of Unum Therapeutics in a research note on Monday, April 23rd. They set an “overweight” rating and a $20.00 target price on the stock. SunTrust Banks initiated coverage on shares of Unum Therapeutics in a research note on Monday, April 23rd. They set a “buy” rating and a $21.00 target price on the stock. Cowen initiated coverage on shares of Unum Therapeutics in a research note on Monday, April 23rd. They set a “market perform” rating on the stock. Finally, Wedbush initiated coverage on shares of Unum Therapeutics in a research note on Monday, April 23rd. They set an “outperform” rating and a $18.00 target price on the stock.

In other Unum Therapeutics news, Director Liam Ratcliffe acquired 550,000 shares of the company’s stock in a transaction on Tuesday, April 3rd. The shares were purchased at an average cost of $12.00 per share, with a total value of $6,600,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Venture Fund Ix L.P. Atlas acquired 94,052 shares of the company’s stock in a transaction on Tuesday, April 3rd. The stock was acquired at an average cost of $12.00 per share, for a total transaction of $1,128,624.00. The disclosure for this purchase can be found here.

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in shares of Unum Therapeutics in the first quarter valued at $982,000. Highland Capital Management LP bought a new position in shares of Unum Therapeutics in the first quarter valued at $770,000. Point72 Asset Management L.P. bought a new position in shares of Unum Therapeutics in the first quarter valued at $3,599,000. Sabby Management LLC bought a new position in shares of Unum Therapeutics in the first quarter valued at $2,917,000. Finally, Platinum Investment Management Ltd. bought a new position in shares of Unum Therapeutics during the first quarter valued at about $2,499,000. 48.30% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ UMRX traded down $0.19 on Friday, hitting $11.27. 22,302 shares of the company were exchanged, compared to its average volume of 79,723. Unum Therapeutics has a 12 month low of $10.15 and a 12 month high of $12.70.

Unum Therapeutics (NASDAQ:UMRX) last issued its earnings results on Monday, May 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.31). The company had revenue of $2.22 million for the quarter, compared to analyst estimates of $2.45 million. equities research analysts predict that Unum Therapeutics will post -1.56 earnings per share for the current fiscal year.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply